Article · 4 May 2026
ArticlePublished 28 Jun 2024
Effects of Bevacizumab on VEGF/VEGFR and PI3K/AKT Pathways in Cutaneous Ovarian Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To investigate the effect of bevacizumab on epithelial ovarian cancer by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor and phosphoinositide 3-kinase/protein kinase B pathway. OVCAR3 cells were divided into control (group A) and experimental (group B) group. The group A did not receive any treatment, while the group B treated human ovarian cancer cells OVCAR3 with bevacizumab. The cell proliferation was detected by cell counting kit 8, the cell migration and invasion were detected by Transwell assay, and the apoptosis was detected by flow cytometry. The expression of proteins was detected by Western blot. The proliferation, migration and invasion of ovarian cancer cells in the group B were decreased. The apoptosis rate of ovarian cancer cells in the group B was increased, the phosphorylated-phosphoinositide 3-kinase and phosphorylated-protein kinase B protein in the group B was reduced than group A. The vascular endothelial growth factor in ovarian cancer cells in the group B was down-regulated and the vascular endothelial growth factor receptor was increased. Bevacizumab inhibits the development and metastasis of ovarian cancer by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor and phosphoinositide 3-kinase/protein kinase B pathways, which may be a potential strategy for the treatment of the disease.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Indian Journal of Pharmaceutical Sciences.
Article · 21 Apr 2026
In silico molecular docking analysis of bioactive compounds from Kappaphycus alvarezii and Gracilaria debilis against BRCA1 protein
Article · 11 Mar 2026
Trimethoprim and Sulfamethoxazole-Loaded Nanoparticles Coated With Chitosan for Intranasal Delivery to Treat Cerebral Toxoplasmosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Hongbing Qiu”
- BylineArticles whose byline prints “Xiaoming Li”
- BylineArticles whose byline prints “Wenna Qiu”
- BylineArticles whose byline prints “Zhen Xie”